Evidence map›Paper›PMID 25514162›Full record

ArticlePloS one2014

Serotonin/dopamine interactions in a hyperactive mouse: reduced serotonin receptor 1B activity reverses effects of dopamine transporter knockout.

Frank Scott Hall, Ichiro Sora, René Hen, George R Uhl

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Serotonin dysfunction in ADHD.Journal of neurodevelopmental disorders · 2025
    Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Frank Scott HallDepartment of Pharmacology, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, Ohio, United States of America; Molecular Neurobiology Branch, National Institute on Drug Abuse - Intramural Research Program, Baltimore, Maryland, United States of America.
Ichiro SoraKobe University Graduate School of Medicine, Kobe, Japan.
René HenDepartments of Pharmacology, Neuroscience and Pharmacology, Columbia University, New York, New York, United States of America; Division of Integrative Neuroscience, The New York State Psychiatric Institute, New York, New York, United States of America.
George R UhlMolecular Neurobiology Branch, National Institute on Drug Abuse - Intramural Research Program, Baltimore, Maryland, United States of America.
National Institute on Drug Abuse · USKobe University · JPNeurosciences Institute · US

Funding

Intramural NIH HHS
6 · The paper itself

Abstract

Knockout (KO) mice that lack the dopamine transporter (SL6A3; DAT) display increased locomotion that can be attenuated, under some circumstances, by administration of drugs that normally produce psychostimulant-like effects, such as amphetamine and methylphenidate. These results have led to suggestions that DAT KO mice may model features of attention deficit hyperactivity disorder (ADHD) and that these drugs may act upon serotonin (5-HT) systems to produce these unusual locomotor decreasing effects. Evidence from patterns of brain expression and initial pharmacologic studies led us to use genetic and pharmacologic approaches to examine the influence of altered 5-HT1B receptor activity on hyperactivity in DAT KO mice. Heterozygous 5-HT1B KO and pharmacologic 5-HT1B antagonism both attenuated locomotor hyperactivity in DAT KO mice. Furthermore, DAT KO mice with reduced, but not eliminated, 5-HT1B receptor expression regained cocaine-stimulated locomotion, which was absent in DAT KO mice with normal levels of 5-HT1B receptor expression. Further experiments demonstrated that the degree of habituation to the testing apparatus determined whether cocaine had no effect on locomotion in DAT KO or reduced locomotion, helping to resolve differences among prior reports. These findings of complementation of the locomotor effects of DAT KO by reducing 5-HT1B receptor activity underscore roles for interactions between specific 5-HT receptors and dopamine (DA) systems in basal and cocaine-stimulated locomotion and support evaluation of 5-HT1B antagonists as potential, non-stimulant ADHD therapeutics.

Indexed as

AnimalsAttention Deficit Disorder with HyperactivityCocaineDopamineDopamine Plasma Membrane Transport ProteinsDopamine Uptake InhibitorsLocomotionMiceMice, Inbred C57BLMice, KnockoutMotor ActivityPiperidonesReceptor, Serotonin, 5-HT1BSerotoninSerotonin 5-HT1 Receptor AntagonistsSpiro CompoundsCocaineDopamineDopamine Plasma Membrane Transport ProteinsDopamine Uptake InhibitorsPiperidonesReceptor, Serotonin, 5-HT1BSB 22489GSerotoninSerotonin 5-HT1 Receptor AntagonistsSpiro Compounds

Identifiers

PMID25514162
PMCPMC4267809
OpenAlexW2052096551

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.